RHPN2

Across TCGA pan-cancer cohorts, RHPN2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RHPN2 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RHPN2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RHPN2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where RHPN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.529	0.237	<.001	54	view →
CCRCC	DFS	Tertile	II,III,IV	0.928	0.105	.006	24	view →
UCEC	DFS	Tertile	II,III,IV	0.905	0.396	.014	8	view →
HNSC	OS	Quartile	All	0.654	0.867	.029	6	view →
LUAD	OS	Tertile	III,IV	0.394	0.815	.009	6	view →
LSCC	OS	Quartile	II,III,IV	0.835	1.000	.049	1	view →
GBM	DFS	Quartile	All	0.628	0.837	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RHPN2–PDAC (DFS)

Open the PDAC breakdown →